TLP
PTGX icon

Tri Locum Partners’s Protagonist Therapeutics PTGX Stock Holding History

Tri Locum Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33,750
Closed -$932K – 79
2023
Q2 		$932K Sell
33,750
-99,702
-75% -$2.5M 0.35% 38
2023
Q1 		$3.07M Buy
+133,452
New +$2.24M 0.93% 32
2022
Q2 		– Sell
-769,250
Closed -$9.3M – 59
2022
Q1 		$18.2M Buy
769,250
+455,321
+145% +$12.8M 7.12% 2
2021
Q4 		$10.7M Buy
+313,929
New +$9.92M 4.23% 9
2021
Q3 		– Sell
-341,650
Closed -$15.3M – 41
2021
Q2 		$15.3M Buy
341,650
+84,564
+33% +$2.79M 5.02% 7
2021
Q1 		$6.66M Sell
257,086
-2,197
-0.8% -$55.6K 1.65% 16
2020
Q4 		$5.23M Buy
+259,283
New +$5.58M 1.9% 16

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tri Locum Partners's PTGX Position: Q3 2023 in Review

Tri Locum Partners sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 33,750 shares — an estimated $932K sold.

Tri Locum Partners first reported a position in PTGX in Q4 2020 and held it in 7 quarters. The position peaked at $18.2M in Q1 2022. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • Tri Locum Partners reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Tri Locum Partners sold 33,750 Protagonist Therapeutics shares in Q3 2023, an estimated $932K.
  • Tri Locum Partners first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 7 quarters.
  • Tri Locum Partners's Protagonist Therapeutics position peaked at $18.2M in Q1 2022.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.